That's very confusing to me. I would ask the nurse to provide you with more information. I have never heard of a man being warned about CellCept use. We were told that should Jenna choose to get pregnant she would have to switch to another immunosuppressant prior to conception to avoid birth defects which can include deformities of the head, neck and shoulders.
This warning is directly from CellCept's website:
http://www.cellceptforliving.com/If you are a woman of childbearing age, you must use highly effective (2 methods) contraception 4 weeks prior to starting CellCept therapy, and continue contraception until 6 weeks after stopping CellCept treatment, unless abstinence is the chosen method. A patient who is planning a pregnancy should not use CellCept unless she cannot be successfully treated with other immunosuppressant drugs. If you are considering pregnancy, be sure to talk to your doctor.There's also this recent news story. Again, it only refers to women:
Roche's CellCept raises birth defect risks: FDAMon Oct 29, 2007 10:00pm GMT
WASHINGTON (Reuters) - The Food and Drug Administration said on Monday the Roche Holding AG organ rejection drug, CellCept, boosts the risk of pregnancy loss in the first trimester and also the risk of congenital malformations.
The FDA said it added a new boxed warning to the drug's label about the increased fetal risk of ear and facial deformities and problems in limbs, the heart and other organs. Data collected from a national registry led to the new warning, the FDA said.
CellCept should not be given until a negative pregnancy test is confirmed within one week prior to therapy, the FDA said. The drug may reduce the effectiveness of birth control pills, the FDA said.
CellCept is used to help prevent kidney, liver and heart transplant rejection.
The FDA in its warning cited a review of postmarketing data from 1995 to 2007 that found among 77 women exposed to the drug, 25 had a spontaneous abortion and 14 had a deformed infant or fetus.
Because dangerous side effects are reported voluntarily to the FDA, it is difficult to determine how common the adverse outcomes are, the FDA said.
Prehuman studies of the drug did find some signs of fetal defects, the agency said.
http://uk.reuters.com/article/healthNews/idUKN2920254920071029?feedType=RSS&feedName=healthNews